Incivekâ„¢ (Telaprevir) - Your Questions Answered

[Guest guest]

Incivekâ„¢ (Telaprevir) - Your Questions Answered

With the approval of Incivekâ„¢ (telaprevir) for the treatment of those with Hepatitis C, genotype 1, and the potential to cut treatment time to just 24 weeks, many questions arise. Here we have summarized some of these questions.

by Editors at Hepatitis-Central.com

With the approval of a new treatment option for those with Hepatitis C genotype 1 there is bound to be questions. Based on the information provided by Vertex, developer of Incivekâ„¢, we have provided summaries for many of the questions that are being asked. Learning more about this new combination therapy and discussing this information with your healthcare provider are essential.

Simply click on any of the links below for more details:

What is Incivekâ„¢ (telaprevir)?

What is the dosage for Incivekâ„¢ (telaprevir)?

Does the dosage and administration of Incivekâ„¢ (telaprevir) differ for various people?

When is Incivekâ„¢ contraindicated?

What types of adverse reactions were reported when taking Incivekâ„¢?

Are there any other warnings one should know regarding Incivekâ„¢ combination therapy?

At what point would one know the Incivekâ„¢ combination therapy is not working?

Can those co-infected with HIV and Hepatitis C begin Incivekâ„¢ combination therapy?

When can I get a prescription for Incivekâ„¢ (telaprevir)?

How can I get assistance paying for Incivekâ„¢ (telaprevir)? Is Incivekâ„¢ covered by insurance?

http://www.hepatitis-central.com/mt/archives/2011/05/fda_approved_in_1.html